Merck (MRK) Q3 2026 Earnings Call Transcript
On its third-quarter 2026 earnings call, Merck discussed generic headwinds ahead in 2027 alongside new product launches and growth of its WINREVAIR medicine.
fool.com ·
支援資產
開啟 Mo
默沙東
24/7
-
-所選期間
-相較美股收盤
新聞
Merck One of Top Large-Cap Biopharma Picks-Analyst
Benzinga reported that Merck beat Q3 estimates on oncology strength and raised guidance, and that Guggenheim is watching pipeline progress ahead of Keytruda patent loss.
benzinga.com ·
代幣
- 代幣
- MRKc
- 每枚代幣對應股數
- 1.00000000 MRK